Background: In pivotal studies with direct-acting antivirals (DAAs), rates of sustained virological response in hepatitis C genotype 1 infection are >90%. Objective: The objective of this article is to assess real-world safety and effectiveness of DAA treatment in a prospective multicenter registry study. Methods: The German Hepatitis C-Registry includes 6606 patients with genotype 1 from 246 centers, treated between February 2014 and June 2016 at the discretion of the physician. Results: A total of 4846 patients completed treatment and follow-up; 51% of these patients were treatment experienced and 28% had liver cirrhosis. Comorbidities were reported in 76% of patients, including HIV co-infection in 8%. SVR12 was 92% with 91% in GT1a and 93% in GT1b. HIV co-infected patients (n ¼ 247) had an SVR12 of 92%. Treatment was discontinued prematurely in 2.5%. In multivariate analysis, SVR12 was dependent on the choice of antiviral regimen (OR 1.33 (1.24-1.43); p < 0.001), negatively associated with presence of liver cirrhosis (OR 0.71 (0.56-0.89); p < 0.003) and positively associated with female gender (OR 1.52 (1.21-1.91); p < 0.001). Conclusion: Data from this real-world registry show SVR12 rates close to those obtained in clinical studies. Discontinuation rates are low, confirming good tolerance of the regimens and good adherence of patients (Trial registration number DRKS00009717, German Clinical Trials Register, DRKS). What are the significant and/or new findings of this study?
Introduction
Worldwide up to 103 million people are chronically infected with hepatitis C (HCV) and it is estimated that about 1 million to 4 million people die from HCV-associated diseases per year.
1,2 Sequelae of HCV infection include development of liver cirrhosis and hepatocellular carcinoma, which are reduced after successful treatment of HCV infection. 3 Starting in 2011 with the approval of the first direct-acting antivirals (DAAs) telaprevir and boceprevir, used in combination with pegylated-interferon (IFN) and ribavirin (RBV), rates of sustained virological response (SVR) have continuously improved. 4 The approval of sofosbuvir (SOF), simeprevir (SIM) and daclatasvir (DCV) in 2014 led to improved efficacy combined with a much better tolerability. 5, 6 The combination of SIM/SOF showed SVR rates of 79%-100% [7] [8] [9] and the combination of SOF/DCV 95%-100%. 6 In early 2015 sofosbuvir and ledipasvir (SOF/LDV) and ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) and dasabuvir (DSV) were approved following phase III studies with SVR rates >90% for HCV genotype 1 (GT1). 10, 11 High SVR results were also achieved in difficult-to-treat patients, albeit treatment had to be prolonged to 24 weeks or RBV had to be added. [11] [12] [13] [14] [15] Presently, several of the aforementioned combinations of DAAs are recommended for the treatment of HCV infection by current guidelines, varying in treatment duration from 8 to 24 weeks and the possible addition of RBV tailored to the condition of the patient. 16 However, treatment with the new DAAs is associated with significant immediate costs for health care systems. 17 In addition, population-based modeling suggests that a significant effect on HCV mortality on a population level can be observed only if a substantial increase in the number of successfully treated patients is achieved. 18 Therefore, successful treatment of HCV infection depends not only on the efficacy of the antiviral drugs, but also on patient and health care-related factors. Accordingly, effectiveness of antiviral therapy may vary in a real-world setting.
The health care system in Germany allows initiation of antiviral therapy with any European Medicine Agency (EMA)-approved drug by physician discretion. Furthermore, treatment is not centralized and can be initiated by any physician. However, costs per SVR are estimated to be between 41,766E and 80,824E in Germany, with higher prices paid for longer treatment durations in difficult-to-treat patients. 19 Physicians may be penalized by claim backs of medication costs if they did not use the most cost-efficient therapy. We here assess the effectiveness of the new DAA in the German health care system based on data from a large nationwide cohort.
Material and methods

German Hepatitis C-Registry
The German Hepatitis C-Registry (Deutsches Hepatitis C-Register, DHC-R) is a prospective, open-label, multicenter, non-interventional study as described previously. 20, 21 Inclusion criteria were chronic hepatitis C virus (HCV) infection with detectable HCV-RNA and !18 years of age. Exclusion criteria were pregnancy and non-reliable contraception. The choice of antiviral therapy was at the discretion of the physician. Main parameters of interest included demographic data, medical history, viral genotype and viral load, laboratory parameters, fibrosis assessment (transient elastography and/or histology), concomitant medication, virological outcomes and adverse events. Data were recorded via a web browser-based Electronic Data Capture system and reviewed by study monitors (see supplements for details). 
Patient population
Assessment of endpoints
The safety population (intention-to-treat, ITT1) consists of patients who started antiviral therapy and for whom at least the baseline visit was documented. The modified ITT effectiveness analysis (ITT3) included all patients from the safety population (ITT1) with SVR12 data. For the per protocol analysis (PP), nonadherent patients, patients with missing data or patients lost-to-follow-up were excluded (Figure 1 ). Primary endpoint was the proportion of patients who achieved SVR12. SVR12 was defined as undetectable HCV-RNA 70-153 days after end of treatment (EoT). 
Statistics
Because of the ongoing nature of the study, the status of data for this analysis was frozen on June 30, 2016. The statistical analysis was descriptive to reflect the clinical routine as intended by the physicians. Further details are described in the supplements.
Results
Patient population and treatment regimens
Overall, 6606 patients with HCV GT1 infection were included in the study. A total of 498 patients were only assessed for therapy, but not treated. A total of 6108 patients received treatment (safety population, ITT1) and 4846 patients received treatment and a follow-up visit 12 weeks after end of treatment (effectiveness population, ITT3). There were 237 patients who were lost to follow-up or had missing data, thus, the perprotocol-analysis consists of 4609 patients (Figure 1 ).
Baseline characteristics of the screened and treated patients are shown in Table 1 . In summary, patients who were treated were older (median 55 AE 12.5 vs 51.5 AE 13.5), more likely to be treatment experienced (49.7% vs 27.5%) and had a higher prevalence of cirrhosis (27.8% vs 7.4%). However, human immunodeficiency virus (HIV) prevalence was slightly lower (8.2% vs 12.0%).
Among all patients who started treatment (ITT1), cirrhosis was diagnosed in 1355 patients, of whom 1175 patients were classified as Child-Pugh A (86.7%), 156 patients as Child-Pugh B (11.5%) and 24 patients as Child-Pugh C (1.8%). Comorbidities were present in 4615 patients (75.6%). The most common comorbidities were cardiovascular diseases (27.2%), psychiatric diseases (15.1%), diabetes (10.1%) and thyroid dysfunction (9.8%). Chronic respiratory diseases were present in 5.3% of patients, malignancies, renal insufficiency and neurological comorbidities in 3.9%, 2.6% and 2.8%, respectively. Liver-related behavioral risk factors were drug abuse, which affected 14.4% of all treated patients, and alcohol abuse in 3.9% of patients. No major differences could be detected between the safety population and the effectiveness population (ITT3) as well as the population included in the per-protocol analysis ( Table 1) .
The choice of treatment regimens varied distinctly by time period (Figure 2 ). After approval of SOF in January 2014 the majority of patients (88.4%) were treated with PEG-IFN/RBV þ DAA (SOF/TVR/ BOC). IFN-free treatment was rapidly adopted after approval of SIM in May 2014 and DCV in August 2014 with 84.2% of patients receiving an SOF-based IFN-free treatment. LDV/SOF was approved in November 2014 and OBV/PTV/r/DSV in January 2015, accounting for 94.8% of all treatments after their approval. IFN-based treatment declined to less than 1% of all treatments prescribed during this period. In addition to the uptake of IFN-free treatment a 10-fold increase in absolute numbers of treated patients within the registry was observed ( Figure 2 ).
In total, 373 patients completed an IFN-based therapy (7.7%) and 4473 patients completed IFN-free treatment (92.3%). Among these patients, 890 patients (19.9%) were treated for eight weeks, 2794 patients for 12 weeks (62.5%) and 422 patients for 24 weeks (9.5%). A total of 363 patients received a therapy with individualized treatment length other than eight, 12 or 24 weeks (8.1%). Complete data on used treatment regimens can be found in Supplemental Table S1 . Treatment regimens varied also by the presence of cirrhosis. Usage of IFN-free treatment regimens for 24 weeks was highly associated with presence of cirrhosis (346/422 patients, 82.0%, p < 0.0001). However, the majority of patients with cirrhosis received IFN-free treatment for 12 weeks or less (n ¼ 849 patients, 61.6% of all cirrhotics; data available for 4106 patients with distinct treatment durations).
Effectiveness of treatment
Overall, SVR12 was achieved in 4445/4846 patients (91.7%; ITT3). SVR12 rates were >90% for approved IFN-free treatment regimens except the combination of SIM/SOF without RBV for 12 weeks in mostly cirrhotic patients, which showed an SVR of 87.8%. The IFN-based combination SOF/RBV/PEG-IFN resulted in an SVR12 rate of 84.3% (Figure 3(a) ). Complete data for all treatment regimens are shown in Supplemental Table S1 . Because of the real-world nature of this study, the baseline characteristics of the patients treated with the various treatment regimens are different, thus, SVR12 rates of the different regimens can't be directly compared to each other. SVR12 rates for HCV genotype 1b were higher with 92.5% (2413/2608) vs 90.5% (1798/1986) for genotype 1a (p < 0.05) (Figure 3(b) ). Previous treatment with (PEG)-IFN or DAAs did not result in lower SVR12 rates in comparison to treatment-naı¨ve patients with SVR12 rates of 92.9%, 91.9% and 90.7%, respectively. Of the 590 patients with previous DAA-based treatment, none of the patients had a non-response to treatment. The majority of these patients received retreatment with a combination of LDV/SOF AE RBV or DCV/SOF for 12-24 weeks. Details about specific treatment regimens in DAA treatment-experienced patients and the respective SVR rates are shown in Table 2 .
Patients with HIV co-infection had similar SVR12 rates with 92.3%. Lower SVR12 rates were observed in patients with advanced cirrhosis (Child-Pugh A 90.5%, Child-Pugh B 84.1% and Child-Pugh C 83.3%) and on opioid-substitution therapy (SVR12 86.6%, OST). The per-protocol analysis showed comparable SVR12 rates in comparison to the ITT3 analysis except for patients with Child-Pugh C cirrhosis (83.3% vs 93.3%, 15/18 vs 14/15) and OST (86.6% vs 96.3%, 317/366 vs 315/327). In these groups the difference was approximately 10%, indicating a substantial proportion of patients lost to follow-up. Virological response in the OST group was non-inferior to that in patients without OST. Nonresponse and relapse rates were 0.1% and 2.7% for patients without OST and 0.0% and 1.1% for patients with OST, respectively. Treatment discontinuation was more common in patients with OST (3.8% vs 1.3%).
Univariate analysis for genotype subtype, cirrhosis, age !60 years, choice of HCV therapy, gender, platelets <100/nl and initial viral load was performed to assess risk factors for virological non-response. The analysis revealed significant differences for the presence of cirrhosis, platelets, age, HCV therapy and gender (Table 3(a) ). On multivariate analysis chance of SVR was significantly dependent on the choice of antiviral therapy, negatively correlated with presence of cirrhosis and positively correlated with female gender (Table 3(b) ). However, HCV therapy was chosen by the physician based on the preconditions of the patient; therefore, baseline criteria of the populations treated with the various treatment regimens are different and SVR rates of the various treatment regimens are not directly comparable.
Safety of treatment
Adverse events were reported in 3293 patients, affecting 53.9% of the study population (safety population). The most common adverse events affecting >10% of the study population were fatigue and headache (Table 4) . Serious adverse events occurred in 240 patients (3.9%). Common serious adverse events were typical complications of advanced liver disease (i.e. liver malignancy, variceal bleeding; Table 4 ). Death during the study period was noted for 30 patients (0.5%) as the most common serious adverse event. Eight of these patients died while being on treatment. The reasons for death during treatment were upper gastrointestinal bleeding (n ¼ 1), acute or chronic liver failure (n ¼ 2), renal failure, septic peritonitis as complication of diverticulitis and unknown causes in three patients each. Among all patients, 13 patients died from liver-related complications (43.3%), whereas 12 died from reasons not related to liver disease (40.0%). In five patients reason for death was not reported (16.6%). Anemia was a frequent cause of adverse or serious adverse events with 156 (2.6%) and 13 (0.21%) of the safety population affected and is a very common side effect of RBV. Dose adjustment of the antiviral therapy occurred in 181 patients (3.0%). Treatment discontinuations were assessed in the effectiveness population (ITT3). Overall, 122 patients (2.5%) discontinued treatment prematurely. Discontinuations were higher in patients treated with SOF/RBV þ PEG-IFN with 3.3% (Figure 3(a) ). Reasons for premature discontinuation were loss to follow-up in 43 patients (35.2%), poor adherence in 35 patients (28.7%), adverse events in 24 patients (19.7%), inadequate virological response in 16 patients (13.1%), death in eight patients (6.6%) and other reasons in six patients (4.9%). Although IFN-based treatment was used in only a minority of patients (373 patients, 7.7%), IFN-based treatments accounted for 25% (6/24) of all treatment discontinuations due to adverse events.
Discussion
The results from this large real-world registry with 6606 patients with HCV genotype 1 infection confirm the high SVR rates >90% from pivotal studies in a real-world scenario. Effectiveness was high in HCV genotype 1a and 1b, as well as compensated cirrhosis and HIV coinfected patients. This confirms the finding of several studies that HIV co-infection is not associated with reduced SVR rates anymore. In this cohort HIV co-infected patients had a slightly higher SVR rate of 92.3% in comparison to non-HIV infected patients. Similar results have also been shown in the German GECCO study for HIV co-infected patients. 22 Patients with compensated cirrhosis had comparable SVR rates to non-cirrhotic patients at 90.5%. However, treatment regimens were modified according to cirrhosis status (Figure 3(a) ). Lower rates are observed in patients with decompensated cirrhosis with 84.1% and 83.3% for Child-Pugh B and ChildPugh C cirrhosis, respectively. Comparable results have been demonstrated in pivotal studies with combinations of SOF/LDV and SOF/DCV. 23, 24 Several dynamic changes in the use of DAA combinations in this real-world setting were observed. Whereas INF-based therapy was the mainstay of therapy in early 2014, a dramatic shift to INF-free treatment to late 2014 could be detected. This may reflect guideline recommendations and the results of pivotal studies showing higher SVR rates and lower frequency of adverse events with IFN-free treatment. SVR rates of IFN-based therapy were lower with 84.3% for SOF þ PEG-IFN þ RBV representing a mix of premature treatment discontinuation together with lower efficacy.
Simultaneously with the decrease in IFN-based treatment, a 10-fold increase in treated patients can be observed within the registry. Although this finding cannot generalize an overall uptake in HCV treatment in Germany, this finding may resemble an increased acceptance of HCV treatment by physicians and patients. Certainly, the awareness of the results from phase III and IV studies is a main driver for treatment uptake and the choice of treatment. In a recent paper the increase in treated patients with hepatitis C in Germany was reported to triple from 2014 to 2015. 25 All health care systems operate under cost constraints and costs can influence treatment decisions, which may lead to suboptimal effectiveness or undertreatment. Regarding the choice of treatment, a key finding is that treatment for 24 weeks was strongly associated with presence of cirrhosis, essentially reserving the longest and most costly treatment strategy for a minority of difficult-to-treat patients. Importantly, most patients with early-stage cirrhosis were still treated for 12 weeks with comparable SVR rates, mainly with a regimen including ribavirin. This is associated with substantial cost savings for the health care system and shows that physicians achieved very good results by tailoring treatment according to the patient's preconditions taking treatment cost into account.
However, patients with decompensated cirrhosis Child-Pugh stage B and C demonstrated lower SVR rates of 84.1% and 83.1%. These results are in line with outcomes from phase II and III studies. 23, 24 It is important to note that only a few patients with Child-Pugh C cirrhosis were treated in this large cohort (24/6108, 0.4%). This may be due to center selection, as these patients are candidates for liver transplantation. A Model for End-Stage Liver Disease (MELD) score !27 has been suggested as a threshold above which treatment may have detrimental effects on the patient and treatment after liver transplantation may be the better option. 26 Treatment retention was high, indicated by a low treatment discontinuation rate of 2.3%. However, discrepancies between the per-protocol analysis and the ITT analysis were observed for patients on OST. Although the virological response was not inferior to patients without OST, rates of treatment discontinuation and loss of follow-up were higher in these patients, explaining the differences in observed SVR rates and partly contradicting findings from phase III studies, showing no influence of OST on treatment. 27 Supportive measures have been shown to increase retention and SVR rates in these difficult-to-treat patients. 28 In conclusion, the data of the real-world DHC-R validate effectiveness and safety for treatment regimens that have been approved with limited data for certain subgroups. It shows dynamic changes in treatment uptake and treatment choice based on several events, demonstrating timely treatment adjustments by the responsible physicians after release of new treatment options and guideline recommendations. A high success rate was achieved even in more difficult-to-treat patients, thereby demonstrating a balance between patients' needs and demands of the health care system.
